Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 10:6:20703.
doi: 10.1038/srep20703.

The role of Xpert MTB/RIF in diagnosing pulmonary tuberculosis in post-mortem tissues

Affiliations

The role of Xpert MTB/RIF in diagnosing pulmonary tuberculosis in post-mortem tissues

Alberto L García-Basteiro et al. Sci Rep. .

Abstract

The extent to which the Xpert MTB/RIF (Gene Xpert) contributes to tuberculosis (TB) diagnosis in samples other than sputum and cerebrospinal fluid remains uncertain. We aimed to assess the role of Xpert MTB/RIF for detecting M. tuberculosis in post-mortem tissues. We conducted a study among 30 complete diagnostic autopsies (CDA) performed at the Maputo Central Hospital (Mozambique). Lung tissues were screened for TB in all cases. In addition other tissues were tested when compatible lesions were identified in the histological exam. We used in-house real time PCR and LAMP assays to confirm the presence of M. tuberculosis DNA. The diagnosis of tuberculosis at death was established based on microbiological and histopathological results. Eight out of 30 cases (26.7%) were diagnosed of tuberculosis. Xpert had a sensitivity to detect TB in lung tissue of 87.5% (95% CI 47.3-99.7) and a specificity of 95.7% (95% CI: 78.1-99.9). In-house DNA amplification methods and Xpert showed 93.6% concordance for lung tissue and 100% concordance for brain and liver tissues. The final cause of death was attributable to tuberculosis in four cases. Xpert MTB/RIF may represent a valuable, easy-to perform technique for post-mortem TB diagnosis.

PubMed Disclaimer

References

    1. World Health Organization. Global Tuberculosis Report 2014. (WHO/HTM/TB/2014.08, 2014).
    1. Uplekar M. et al. WHO’s new End TB Strategy. Lancet 385, 1799–801 (2015). - PubMed
    1. World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. (WHO/HTM7TB/2014.18, 2014).
    1. World Health Organization. Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. Policy Statement. (WHO/HTM/TB/2011.4, 2011). - PubMed
    1. Steingart K. R. et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst. Rev. 1, CD009593 (2013). - PMC - PubMed

Publication types

MeSH terms